Lixte Biotechnology Holdings Inc (NASDAQ: LIXT) — Healthcare · Share Price, Chart & Market Data
About: Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.50 (-2.78%)
LIXTLixte Biotechnology Holdings Inc
Loading watchlist status…
Trade LIXT now
Lixte Biotechnology Holdings Inc share price
LIXT price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
30 Apr, 1:47 am GMT+0
LIXT price performance
-12.06%
5D
11.821%
1M
-8.854%
YTD
172.162%
1Y
LIXT price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
NASDAQ rank
N/A
Sector Rank
N/A
Delayed
30 Apr, 1:47 am GMT+0
LIXT details
LIXT Market Signals